trending Market Intelligence /marketintelligence/en/news-insights/trending/dSNLqZgvlSbB-HQ0uCR4HA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Apellis closes $117.3M common stock offering

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Apellis closes $117.3M common stock offering

Apellis Pharmaceuticals Inc. closed a public offering of 6.9 million common shares priced at $17 each to raise $117.3 million in gross proceeds.

Shares sold include the additional 900,000 stocks underwriters could have bought as part of their overallotment option,

Citigroup, J.P. Morgan and Cowen acted as joint book-running managers for the offering, while Cantor Fitzgerald & Co. acted as lead manager.

Crestwood, Ky.-based Apellis Pharmaceuticals develops therapies for autoimmune and inflammatory diseases.